Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/11096167/ below:

The effect of fecal occult-blood screening on the incidence of colorectal cancer

Clinical Trial

Affiliations

• ¹ Exponent, Menlo Park, Calif 94025, USA. jmandel@exponent.com

• PMID: 11096167
• DOI: 10.1056/NEJM200011303432203

Item in Clipboard

Clinical Trial

J S Mandel et al. N Engl J Med. 2000.

• ¹ Exponent, Menlo Park, Calif 94025, USA. jmandel@exponent.com

• PMID: 11096167
• DOI: 10.1056/NEJM200011303432203

Item in Clipboard

Background: Both annual testing for fecal occult blood and biennial testing significantly reduce mortality from colorectal cancer. However, the effect of screening on the incidence of colorectal cancer remains uncertain, despite the diagnosis and removal of precancerous lesions in many persons who undergo screening.

Methods: We followed the participants in the Minnesota Colon Cancer Control Study for 18 years. A total of 46,551 people, most of whom were 50 to 80 years old, were enrolled between 1975 and 1978 and randomly assigned to annual screening, biennial screening, or usual care (the control group). Those assigned to the screening groups were asked to prepare and submit two samples from each of three consecutive stools for guaiac-based testing. Those with at least one positive slide in the set of six were offered a diagnostic examination that included colonoscopy. Screening was conducted between 1976 and 1982 and again between 1986 and 1992. Study participants have been followed with respect to newly diagnosed cases of colorectal cancer and deaths. Follow-up has been more than 90 percent complete.

Results: During the 18-year follow-up period, we identified 1359 new cases of colorectal cancer: 417 in the annual-screening group, 435 in the biennial-screening group, and 507 in the control group. The cumulative incidence ratios for colorectal cancer in the screening groups as compared with the control group were 0.80 (95 percent confidence interval, 0.70 to 0.90) and 0.83 (95 percent confidence interval, 0.73 to 0.94) for the annual-screening and biennial-screening groups, respectively. For both screening groups, the number of positive slides was associated with the positive predictive value both for colorectal cancer and for adenomatous polyps at least 1 cm in diameter.

Conclusions: The use of either annual or biennial fecal occult-blood testing significantly reduces the incidence of colorectal cancer.

PubMed Disclaimer

• Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

  Mandel JS, Church TR, Ederer F, Bond JH. Mandel JS, et al. J Natl Cancer Inst. 1999 Mar 3;91(5):434-7. doi: 10.1093/jnci/91.5.434. J Natl Cancer Inst. 1999. PMID: 10070942

• Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

  Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Mandel JS, et al. N Engl J Med. 1993 May 13;328(19):1365-71. doi: 10.1056/NEJM199305133281901. N Engl J Med. 1993. PMID: 8474513 Clinical Trial.

• Fecal occult blood testing and the incidence of colorectal cancer.

  Singer RB. Singer RB. J Insur Med. 2002;34(2):89-91. J Insur Med. 2002. PMID: 15305783 Clinical Trial.

• Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

  Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Hewitson P, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001216. doi: 10.1002/14651858.CD001216.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253456 Free PMC article. Review.

• From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening.

  Greenwald B. Greenwald B. Gastroenterol Nurs. 2005 Mar-Apr;28(2):90-6. doi: 10.1097/00001610-200503000-00002. Gastroenterol Nurs. 2005. PMID: 15832108 Review.

• Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems.

  Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA; PROSPR Consortium. Burnett-Hartman AN, et al. Am J Prev Med. 2016 Oct;51(4):e107-15. doi: 10.1016/j.amepre.2016.02.025. Epub 2016 Apr 1. Am J Prev Med. 2016. PMID: 27050413 Free PMC article.

• Korean guidelines for colorectal cancer screening and polyp detection.

  Lee BI, Hong SP, Kim SE, Kim SH, Kim HS, Hong SN, Yang DH, Shin SJ, Lee SH, Park DI, Kim YH, Kim HJ, Yang SK, Kim HJ, Jeon HJ; Multi-Society Task Force for Development of Guidelines for Colorectal Polyp Screening, Surveillance and Management. Lee BI, et al. Clin Endosc. 2012 Mar;45(1):25-43. doi: 10.5946/ce.2012.45.1.25. Epub 2012 Mar 31. Clin Endosc. 2012. PMID: 22741131 Free PMC article.

• Aspects of colorectal cancer screening, methods, age and gender.

  Hultcrantz R. Hultcrantz R. J Intern Med. 2021 Apr;289(4):493-507. doi: 10.1111/joim.13171. Epub 2020 Sep 14. J Intern Med. 2021. PMID: 32929813 Free PMC article. Review.

• Cancer Screening Among Older Adults: a Geriatrician's Perspective on Breast, Cervical, Colon, Prostate, and Lung Cancer Screening.

  Kotwal AA, Walter LC. Kotwal AA, et al. Curr Oncol Rep. 2020 Aug 15;22(11):108. doi: 10.1007/s11912-020-00968-x. Curr Oncol Rep. 2020. PMID: 32803486 Free PMC article. Review.

• Screening for Colorectal Cancer: The Role of Clinical Laboratories.

  Toth JF 3rd, Trivedi M, Gupta S. Toth JF 3rd, et al. Clin Chem. 2024 Jan 4;70(1):150-164. doi: 10.1093/clinchem/hvad198. Clin Chem. 2024. PMID: 38175599 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3